ArticleCell stem cell2018
Turning up the Heat with Therapeutic Epigenome Editing.
Article in Cell stem cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Moving Beyond DNA Sequence to Improve Plant Stress Responses.Frontiers in genetics · 2022Review
- Ethics and regulatory considerations for the clinical translation of somatic cell human epigenetic editing.Stem cell reports · 2021Article
- CRISPR/dCas9 platforms in plants: strategies and applications beyond genome editing.Plant biotechnology journal · 2020Review
- Potential application of cell reprogramming techniques for cancer research.Cellular and molecular life sciences : CMLS · 2019Review
- Novel Epigenetic Techniques Provided by the CRISPR/Cas9 System.Stem cells international · 2018Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-Cas9 has been touted for therapeutic genome editing, but limitations include inefficient correction of disease-causing mutations and off-target mutagenesis. In the latest issue of Cell, Liao et al. (2017) show that a modified version of CRISPR-Cas9 can target and activate key therapeutic genes in vivo without altering DNA sequence identity.
Indexed as
Identifiers
29304336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.